To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
Study Type
OBSERVATIONAL
Enrollment
3,409
Otsuka Investigational Site 1
Peoria, Arizona, United States
Otsuka Investigational Site 2
Peoria, Arizona, United States
Otsuka Investigational Site
Tempe, Arizona, United States
Otsuka Investigational Site
Azusa, California, United States
Otsuka Investigational Site
Bakersfield, California, United States
Otsuka Investigational Site
Los Angeles, California, United States
Otsuka Investigational Site
Los Angeles, California, United States
Otsuka Investigational Site
Ontario, California, United States
Otsuka Investigational Site
San Diego, California, United States
Otsuka Investigational Site
Arvada, Colorado, United States
...and 256 more locations
Correlation of change in total kidney volume with ADPKD-related outcomes
Time frame: 1 year
Patient-reported pain
Time frame: every 6 months
SF-12 Scores
Time frame: every 6 months
ADPKD-Impact Scale Score
Time frame: every 6 months
Cost of care
Time frame: every 6 months
EQ-5D Scores
Time frame: Every 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.